Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, March 30, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that Kiklin® Capsules (development code: ASP1585, generic...
Tokyo, March 29, 2012 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have agreed to continue and expand their excellent...
SAN DIEGO & TOKYO, JAPAN, March 29, 2012—Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today the execution of an exclusive...
Staines, 27th March 2012. ASTELLAS PHARMA EUROPE Ltd., the European subsidiary of Tokyo – based Astellas Pharma Inc.(Tokyo:4503) today announced the submission of a Market Authorisation...
Astellas Pharma Inc. (TSE:4503; Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka; ”Astellas”) and UMN Pharma Inc. (Headquarters, Akita; CEO, Shu-ichi Kanazashi; ”UMN”) today...
Sanofi (Headquarters: Paris, France) and Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka) announced today that the two companies agreed to dissolve sanofi-aventis...
Tokyo, February 20, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Sanwa Kagaku Kenkyusho Co., Ltd. (“SKK”; Headquarters: Nagoya;...
Astellas and UCB partner to bring certolizumab pegol to rheumatoid arthritis patients in Japan UCB files certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour...
Tokyo, Japan, January 19, 2012 – The Astellas Asia-Oceania Foundation announced that it donated U.S. dollar 20,000 to the Philippine Urological Association for relief efforts in the Philippines...
TOKYO, JAPAN and SANTA CLARA, CA - January 17, 2012 - Astellas Pharma Inc. (Tokyo: 4503) and XenoPort, Inc. (NASDAQ: XNPT) announced today that Regnite® (gabapentin enacarbil) has received...
Tokyo, January 5, 2012 – Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announces that it will halt exports of Gaster-D 20mg tablets to Korea for a period of three months in accordance with a...
SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Tokyo, December 9, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the Ireland Japan Chamber of Commerce (IJCC, http://www.ijcc.jp/) presented it with a business...
Tokyo, November 11, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that it accepted...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code:...
Tokyo, Japan, November 11, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced today that it is signing the United Nations Global Compact1, which will further reinforce the...
Follow us
